One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Factors Influencing Reintervention Following Ductal Artery Stent Implantation for Ductal-Dependent Pulmonary Blood Flow: Results From the Congenital Cardiac Research Collaborative
Shabana Shahanavaz, Athar M. Qureshi, Christopher J. Petit, Bryan H. Goldstein, Andrew C. Glatz, Holly D. Bauser-Heaton, Courtney E. McCracken, Michael S. Kelleman, Mark A. Law, George T. Nicholson, Jeffrey D. Zampi, Joelle Pettus, and Jeffery Meadows
doi : 10.1161/CIRCINTERVENTIONS.120.010086
Circulation: Cardiovascular Interventions. 2021;14:e010086
Stenting of the patent ductus arteriosus (PDA) is an established palliative option for infants with ductal-dependent pulmonary blood flow. Following initial palliation, reintervention on the PDA stent is common, but risk factors have not been characterized.
Large Diameter Advanta V12 Covered Stent Trial for Coarctation of the Aorta: COARC Study
Elchanan Bruckheimer, Einat Birk, Lee Benson, Gianfranco Butera, Robin Martin, Philip A. Roberts, Martin B.E. Schneider, Stephan Schubert, Horst Sievert, and Carlos C.A. Pedra
doi : 10.1161/CIRCINTERVENTIONS.121.010576
Circulation: Cardiovascular Interventions. 2021;14:e010576
Covered stent implantation for treatment of coarctation of the aorta (CoA) is effective and can prevent aortic wall injury. Prospective studies with long-term follow-up, including imaging, are lacking. We report the acute and long-term outcomes for use of the Large Diameter Advanta V12 covered stent for treatment of native and recurrent CoA.
Anatomical Classification and Posttreatment Remodeling Characteristics to Guide Management and Follow-Up of Neonates and Infants With Coronary Artery Fistula: A Multicenter Study From the Coronary Artery Fistula Registry
Srinath T. Gowda, Larry Latson, Kothandam Sivakumar, Gurumurthy Hiremath, Matthew Crystal, Mark Law, Shabana Shahanavaz, Jeremy Asnes, Surendranath Veeram Reddy, Daisuke Kobayashi, Mazeni Alwi, Fukiko Ichida, Keiichi Hirono, Masahiro Tahara, Atsuhito Takeda, Takaomi Minami, Shelby Kutty, Alan W. Nugent, Thomas Forbes, Lourdes R. Prieto, and Athar M. Qureshi
doi : 10.1161/CIRCINTERVENTIONS.120.009750
Circulation: Cardiovascular Interventions. 2021;14:e009750
Coronary artery fistulas (CAFs) presenting in infancy are rare, and data regarding postclosure sequelae and follow-up are limited.
Alexander C. Fanaroff, Shuang Li, Guillaume Marquis-Gravel, Jay Giri, Renato D. Lopes, Jonathan P. Piccini, and Tracy Y. Wang
Alexander C. Fanaroff, Shuang Li, Guillaume Marquis-Gravel, Jay Giri, Renato D. Lopes, Jonathan P. Piccini, and Tracy Y. Wang
doi : 10.1161/CIRCINTERVENTIONS.121.011232
Circulation: Cardiovascular Interventions. 2021;14:e011232
Older adults with atrial fibrillation (AF) are often treated with the shortest possible duration of antiplatelet/anticoagulant therapy after myocardial infarction (MI) or percutaneous coronary intervention (PCI) due to concern for bleeding. However, the risk of recurrent MI or PCI prompting antiplatelet therapy extension is unknown in this population.
What Happened to the Cycle of Knowledge?
Sorin J. Brener
doi : 10.1161/CIRCINTERVENTIONS.121.011549
Circulation: Cardiovascular Interventions. 2021;14:e011549
Bivalirudin Versus Heparin Monotherapy in ST-Segment–Elevation Myocardial Infarction
Stefan James, Sasha Koul, Jonas Andersson, Oskar Angerås, Pallonji Bhiladvala, Fredrik Calais, Mikael Danielewicz, Ole Fröbert, Per Grimfjärd, Matthias Götberg, Loghman Henareh, Dan Ioanes, Jens Jensen, Rikard Linder, Pontus Lindroos, Elmir Omerovic, Georgios Panayi, Truls Råmunddal, Giovanna Sarno, Anders Ulvenstam, Sebastian Völtz, Henrik Wagner, Helena Wikström, Ollie Östlund, and David Erlinge
doi : 10.1161/CIRCINTERVENTIONS.120.008969
Circulation: Cardiovascular Interventions. 2021;14:e008969
Bivalirudin was not superior to unfractionated heparin in patients with myocardial infarction (MI) treated with percutaneous coronary intervention and no planned use of GPI (glycoprotein IIb/IIIa inhibitors) in contemporary clinical practice of radial access and potent P2Y12-inhibitors in the VALIDATE-SWEDEHEART randomized clinical trial (Bivalirudin Versus Heparin in STEMI and NSTEMI Patients on Modern Antiplatelet Therapy–Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies Registry).
Prognostic Impact of Pancoronary Quantitative Flow Ratio Assessment in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes
Aslihan Erbay, Lisa Penzel, Youssef S. Abdelwahed, Jens Klotsche, Andrea Heuberger, Anne-Sophie Schatz, Julia Steiner, Arash Haghikia, David Sinning, Georg M. Fröhlich, Ulf Landmesser, Barbara E. Stähli, and David M. Leistner
doi : 10.1161/CIRCINTERVENTIONS.121.010698
Circulation: Cardiovascular Interventions. 2021;14:e010698
Quantitative flow ratio (QFR) has been introduced as a novel angiography-based modality for fast hemodynamic assessment of coronary artery lesions and validated against fractional flow reserve. This study sought to define the prognostic role of pancoronary QFR assessment in patients with acute coronary syndrome (ACS) including postinterventional culprit and nonculprit vessels.
Canadian Multicenter Chronic Total Occlusion Registry: Ten-Year Follow-Up Results of Chronic Total Occlusion Revascularization
Bradley H. Strauss, Merril L. Knudtson, Asim N. Cheema, P. Diane Galbraith, Gabby Elbaz-Greener, Wael Abuzeid, Kayley A. Henning, Feng Qiu, and Harindra C. Wijeysundera
doi : 10.1161/CIRCINTERVENTIONS.121.010546
Circulation: Cardiovascular Interventions. 2021;14:e010546
Chronic total occlusions (CTO) occur in nearly 20% of coronary angiograms. CTO revascularization, either by percutaneous coronary intervention (PCI) or coronary artery bypass grafting surgery (CABG), is infrequently performed, approximately one-third of cases. Long-term outcomes are unknown. The objective of the study was to determine whether early CTO revascularization of patients, either by CABG or PCI, was associated with improved clinical outcomes.
Coronary Revascularization in Patients With Coronary Chronic Total Occlusions
Salman Allana and Emmanouil S. Brilakis
doi : 10.1161/CIRCINTERVENTIONS.121.011524
Circulation: Cardiovascular Interventions. 2021;14:e011524
Contemporary Clinical and Coronary Anatomic Risk Model for 30-Day Mortality After Percutaneous Coronary Intervention
Jacob A. Doll, Colin I. O’Donnell, Meg E. Plomondon, and Stephen W. Waldo
doi : 10.1161/CIRCINTERVENTIONS.121.010863
Circulation: Cardiovascular Interventions. 2021;14:e010863
Percutaneous coronary intervention (PCI) procedures are increasing in clinical and anatomic complexity, likely increasing the calculated risk of mortality. There is need for a real-time risk prediction tool that includes clinical and coronary anatomic information that is integrated into the electronic medical record system.
Reduction in Right Atrial Pressures Is Associated With Hemodynamic Improvements After Transcatheter Edge-to-Edge Repair of the Tricuspid Valve
Madeline K. Mahowald, Rick A. Nishimura, Sorin V. Pislaru, Sunil V. Mankad, Vuyisile T. Nkomo, Ratnasari Padang, Jeremy J. Thaden, Mohamad Alkhouli, Mayra Guerrero, Charanjit S. Rihal, and Mackram F. Eleid
doi : 10.1161/CIRCINTERVENTIONS.121.010557
Circulation: Cardiovascular Interventions. 2021;14:e010557
Investigational transcatheter edge-to-edge repair (TEER) for severe tricuspid regurgitation (TR) has shown promise as an alternative to surgery, but factors influencing outcomes, optimal patient selection, and procedural timing remain incompletely defined. Given the limitations of determining TR severity by conventional echocardiography, our objectives were to determine whether invasive right atrial (RA) pressures performed during the procedure are related to patient outcomes.
Catheter-Based Renal Denervation Therapy: Evolution of Evidence and Future Directions
David E. Kandzari
doi : 10.1161/CIRCINTERVENTIONS.121.011130
Circulation: Cardiovascular Interventions. 2021;14:e011130
Motivated by the persistence of uncontrolled blood pressure and its public health impact, the development and evaluation of device-based therapies for hypertension has advanced at an accelerated pace to complement pharmaceutical and lifestyle intervention strategies. Countering widespread interest from early studies, the lack of demonstrable efficacy for renal denervation (RDN) in a large, sham-controlled randomized trial motivated revision of trial design and conduct to account for confounding variables of procedural technique, medication variability, and selection of both patients and end points. Now amidst varied trial design and methods, several sham-controlled, randomized trials have demonstrated clinically meaningful reductions in blood pressure with RDN. With this momentum, additional studies are underway to position RDN as a potential part of standard therapy for the world’s leading cause of death and disability. In parallel, further studies will address unresolved issues including durability of blood pressure lowering and reduction in antihypertensive medications, late-term safety, and impact on clinical outcomes. Identifying predictors of treatment effect and surveys of patient-reported outcomes and treatment preferences are also evolving areas of investigation. Aside from confirmatory studies of safety and effectiveness, these additional studies will further inform patient selection, expand experience with RDN in broader populations with hypertension, and provide guidance to how RDN may be incorporated into treatment pathways.
Discordance Between Coronary Flow Reserve and the Index of Microcirculatory Resistance Post-Revascularization for ST-Segment–Elevation Myocardial Infarction
Klio Konstantinou, Thomas R. Keeble, John R. Davies, Reto A. Gamma, Kare H. Tang, Osama Alsanjari, Paul A. Kelly, Gerald J. Clesham, and Grigoris V. Karamasis
doi : 10.1161/CIRCINTERVENTIONS.121.010529
Circulation: Cardiovascular Interventions. 2021;14:e010529
Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial
Jeremie Abtan, Deepak L. Bhatt, Claes Held, Tabassome Simon, Kim Fox, Shamir R. Mehta, Robert A. Harrington, Qi Gao, Lawrence A. Leiter, and Ph. Gabriel Steg
doi : 10.1161/CIRCINTERVENTIONS.120.011035
Circulation: Cardiovascular Interventions. 2021;14:e011035
Correction to: Predictors of Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement in Severe Mitral Annular Calcification: An Analysis of the Transcatheter Mitral Valve Replacement in Mitral Annular Calcification Global Registry
doi : 10.1161/HCV.0000000000000084
Circulation: Cardiovascular Interventions. 2021;14:e000084
